Order Article Reprints

Lin H-J, Liang T-L, Chang Y-Y, Liu D-Z, Fan J-Y, Roffler SR, Lin S-Y. Development of Irinotecan Liposome Armed with Dual-Target Anti-Epidermal Growth Factor Receptor and Anti-Fibroblast Activation Protein-Specific Antibody for Pancreatic Cancer Treatment. Pharmaceutics. 2022; 14(6):1202. https://doi.org/10.3390/pharmaceutics14061202

Lin, Hung-Jun, Tien-Li Liang, Yao-Yuan Chang, Der-Zen Liu, Jia-Yu Fan, Steve R. Roffler, and Shyr-Yi Lin. 2022. "Development of Irinotecan Liposome Armed with Dual-Target Anti-Epidermal Growth Factor Receptor and Anti-Fibroblast Activation Protein-Specific Antibody for Pancreatic Cancer Treatment" Pharmaceutics 14, no. 6: 1202. https://doi.org/10.3390/pharmaceutics14061202

Lin, H.-J., Liang, T.-L., Chang, Y.-Y., Liu, D.-Z., Fan, J.-Y., Roffler, S. R., & Lin, S.-Y. (2022). Development of Irinotecan Liposome Armed with Dual-Target Anti-Epidermal Growth Factor Receptor and Anti-Fibroblast Activation Protein-Specific Antibody for Pancreatic Cancer Treatment. Pharmaceutics, 14(6), 1202. https://doi.org/10.3390/pharmaceutics14061202